$1.55
3.13% day before yesterday
Nasdaq, Dec 27, 10:16 pm CET
ISIN
US4277461020
Symbol
HRTX
Sector
Industry

Heron Therapeutics Inc Stock price

$1.55
+0.39 33.62% 1M
-1.86 54.55% 6M
-0.15 8.82% YTD
-0.12 7.19% 1Y
-8.69 84.86% 3Y
-22.55 93.57% 5Y
-8.49 84.56% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.05 3.13%
ISIN
US4277461020
Symbol
HRTX
Sector
Industry

Key metrics

Market capitalization $235.75m
Enterprise Value $343.11m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.49
P/S ratio (TTM) P/S ratio 1.71
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 12.13%
Revenue (TTM) Revenue $137.74m
EBIT (operating result TTM) EBIT $-25.92m
Free Cash Flow (TTM) Free Cash Flow $-9.61m
Cash position $70.89m
EPS (TTM) EPS $-0.18
P/E forward negative
P/S forward 1.67
EV/Sales forward 2.44
Short interest 23.40%
Show more

Is Heron Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Heron Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Heron Therapeutics Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Heron Therapeutics Inc forecast:

Buy
100%

Financial data from Heron Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
138 138
12% 12%
100%
- Direct Costs 38 38
44% 44%
28%
99 99
81% 81%
72%
- Selling and Administrative Expenses 98 98
16% 16%
71%
- Research and Development Expense 24 24
56% 56%
18%
-23 -23
80% 80%
-17%
- Depreciation and Amortization 2.63 2.63
12% 12%
2%
EBIT (Operating Income) EBIT -26 -26
79% 79%
-19%
Net Profit -28 -28
77% 77%
-20%

In millions USD.

Don't miss a Thing! We will send you all news about Heron Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Heron Therapeutics Inc Stock News

Neutral
PRNewsWire
5 days ago
SAN DIEGO , Dec. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, announced today the relocation of the Company's headquarters from San Diego, California to Cary, North Carolina, effective January 1, 2025. A majority of Heron's Management Team and corporate employees work from the Cary office, which is near th...
Positive
Seeking Alpha
24 days ago
Heron Therapeutics won a court case securing Cinvanti's patents until 2035, and removing a significant legal overhang on its largest revenue contributor. The court win allows the company to focus on growing the business. Heron missed Q3 revenue estimates, but the company expects a recovery in Cinvanti sales in Q4 due to new account wins, and it shared encouraging trends of Zynrelef and Aponvie.
Neutral
PRNewsWire
25 days ago
— Court Rules in Favor of Heron in Patent Lawsuit Against Fresenius Kabi USA, LLC — SAN DIEGO , Dec. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware ruled in Heron's favor in the Company's patent litigation against Fresenius Kabi USA, LL...
More Heron Therapeutics Inc News

Company Profile

Heron Therapeutics, Inc. is a biotechnology company, which engages in the development of pharmaceutical products for patients suffering from cancer. Its products portfolio include SUSTOL, Cinvanti, HTX-011, and HTX-034. The company was founded in February 1983 and is headquartered in Redwood City, CA.

Head office United States
CEO Craig Collard
Employees 126
Founded 1983
Website www.herontx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today